Skip to main content
Erschienen in: Breast Cancer Research 3/2000

01.06.2000 | Review

Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates

verfasst von: Rania Kairouz, Roger J Daly

Erschienen in: Breast Cancer Research | Ausgabe 3/2000

Einloggen, um Zugang zu erhalten

Abstract

The past decade has seen the definition of key signalling pathways downstream of receptor tyrosine kinases (RTKs) in terms of their components and the protein-protein interactions that facilitate signal transduction. Given the strong evidence that links signalling by certain families of RTKs to the progression of breast cancer, it is not surprising that the expression profile of key downstream signalling intermediates in this disease has also come under scrutiny, particularly because some exhibit transforming potential or amplify mitogenic signalling pathways when they are overexpressed. Reflecting the diverse cellular processes regulated by RTKs, it is now clear that altered expression of such signalling proteins in breast cancer may influence not only cellular proliferation (eg Grb2) but also the invasive properties of the cancer cells (eg EMS1/cortactin).
Literatur
1.
Zurück zum Zitat Pawson T, Scott J: Signaling through scaffold, anchoring and adaptor proteins. Science. 1997, 278: 2075-2080. 10.1126/science.278.5346.2075.CrossRefPubMed Pawson T, Scott J: Signaling through scaffold, anchoring and adaptor proteins. Science. 1997, 278: 2075-2080. 10.1126/science.278.5346.2075.CrossRefPubMed
2.
Zurück zum Zitat Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron. 1992, 9: 383-391.CrossRefPubMed Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron. 1992, 9: 383-391.CrossRefPubMed
3.
Zurück zum Zitat Mayer B: Clamping down on Src activity. Curr Biol. 1997, 7: R295-R298. 10.1016/S0960-9822(06)00141-2.CrossRefPubMed Mayer B: Clamping down on Src activity. Curr Biol. 1997, 7: R295-R298. 10.1016/S0960-9822(06)00141-2.CrossRefPubMed
4.
Zurück zum Zitat Jacobs C, Rubsamen H: Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983, 43: 1696-1702.PubMed Jacobs C, Rubsamen H: Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983, 43: 1696-1702.PubMed
5.
Zurück zum Zitat Rosen N, Bolen JB, Schwartz AM, et al: Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem. 1986, 261: 13754-13759.PubMed Rosen N, Bolen JB, Schwartz AM, et al: Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem. 1986, 261: 13754-13759.PubMed
6.
Zurück zum Zitat Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GEJ: Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. 1989, 49: 516-521.PubMed Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GEJ: Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. 1989, 49: 516-521.PubMed
7.
Zurück zum Zitat Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, et al: Characterisation of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res. 1992, 52: 4773-4778.PubMed Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, et al: Characterisation of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res. 1992, 52: 4773-4778.PubMed
8.
Zurück zum Zitat Verbeek B, Vroom T, Adriaansen-Slot S, et al: c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol. 1996, 180: 383-388. 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.3.CO;2-E.CrossRefPubMed Verbeek B, Vroom T, Adriaansen-Slot S, et al: c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol. 1996, 180: 383-388. 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.3.CO;2-E.CrossRefPubMed
9.
Zurück zum Zitat Daly RJ: Take your partners, please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors. 1999, 16: 255-263.CrossRefPubMed Daly RJ: Take your partners, please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors. 1999, 16: 255-263.CrossRefPubMed
10.
Zurück zum Zitat Pinkas-Kramarski R, Alroy I, Yarden Y: ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signalling. J Mam Gland Biol Neoplasia. 1997, 2: 97-107. 10.1023/A:1026343528967.CrossRef Pinkas-Kramarski R, Alroy I, Yarden Y: ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signalling. J Mam Gland Biol Neoplasia. 1997, 2: 97-107. 10.1023/A:1026343528967.CrossRef
11.
Zurück zum Zitat Egan C, Pang A, Durda D, et al: Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene. 1999, 18: 1227-1237. 10.1038/sj/onc/1202233. This paper represents the first demonstration that a protein tyrosine phosphatase activity directed towards c-Src Tyr530 is upregulated in breast cancer cells.CrossRefPubMed Egan C, Pang A, Durda D, et al: Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene. 1999, 18: 1227-1237. 10.1038/sj/onc/1202233. This paper represents the first demonstration that a protein tyrosine phosphatase activity directed towards c-Src Tyr530 is upregulated in breast cancer cells.CrossRefPubMed
12.
Zurück zum Zitat Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ: Tyrosine kinase signalling in breast cancer: EGF receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000, Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ: Tyrosine kinase signalling in breast cancer: EGF receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000,
13.
Zurück zum Zitat Andrechek ER, Muller WJ: Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2000, Andrechek ER, Muller WJ: Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2000,
14.
Zurück zum Zitat van der Geer P, Hunter T: Receptor protein tyrosine kinases and their signal transduction pathways. Ann Rev Cell Biol. 1994, 10: 251-337. 10.1146/annurev.cellbio.10.1.251.CrossRefPubMed van der Geer P, Hunter T: Receptor protein tyrosine kinases and their signal transduction pathways. Ann Rev Cell Biol. 1994, 10: 251-337. 10.1146/annurev.cellbio.10.1.251.CrossRefPubMed
15.
Zurück zum Zitat Arteaga CL, Johnson MD, Todderud G, et al: Elevated content of the tyrosine kinase substrate phospholipase C-γl in primary human breast carcinomas. Proc Natl Acad Sci USA. 1991, 88: 10435-10439.CrossRefPubMedPubMedCentral Arteaga CL, Johnson MD, Todderud G, et al: Elevated content of the tyrosine kinase substrate phospholipase C-γl in primary human breast carcinomas. Proc Natl Acad Sci USA. 1991, 88: 10435-10439.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chen P, Gupta K, Wells A: Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol. 1994, 124: 547-555.CrossRefPubMed Chen P, Gupta K, Wells A: Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol. 1994, 124: 547-555.CrossRefPubMed
17.
Zurück zum Zitat Daly RJ, Binder MD, Sutherland RL: Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene. 1994, 9: 2723-2727.PubMed Daly RJ, Binder MD, Sutherland RL: Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene. 1994, 9: 2723-2727.PubMed
18.
Zurück zum Zitat Verbeek B, Adriaansen-Slot S, Rijksen G, Vroom T: Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol. 1997, 183: 195-203. 10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.3.CO;2-P.CrossRefPubMed Verbeek B, Adriaansen-Slot S, Rijksen G, Vroom T: Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol. 1997, 183: 195-203. 10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.3.CO;2-P.CrossRefPubMed
19.
Zurück zum Zitat Suen KL, Bustelo XR, Pawson T, Barbacid M: Molecular cloning of the mouse grb2 gene: differential expression of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors. Mol Cell Biol. 1993, 13: 5500-5512.CrossRefPubMedPubMedCentral Suen KL, Bustelo XR, Pawson T, Barbacid M: Molecular cloning of the mouse grb2 gene: differential expression of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors. Mol Cell Biol. 1993, 13: 5500-5512.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on ras. Nature. 1993, 363: 88-92. 10.1038/363088a0.CrossRefPubMed Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on ras. Nature. 1993, 363: 88-92. 10.1038/363088a0.CrossRefPubMed
21.
Zurück zum Zitat Skolnik EY, Batzer A, Li N, et al: The function of GRB2 in linking the insulin receptor to ras signaling pathways. Science. 1993, 260: 1953-1955.CrossRefPubMed Skolnik EY, Batzer A, Li N, et al: The function of GRB2 in linking the insulin receptor to ras signaling pathways. Science. 1993, 260: 1953-1955.CrossRefPubMed
22.
Zurück zum Zitat Cheng A, Saxton T, Sakai R, et al: Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell. 1998, 95: 793-803. This paper demonstrates that Grb2 gene dosage is rate limiting for mammary gland transformation in response to expression of the PyV MT oncogene.CrossRefPubMed Cheng A, Saxton T, Sakai R, et al: Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell. 1998, 95: 793-803. This paper demonstrates that Grb2 gene dosage is rate limiting for mammary gland transformation in response to expression of the PyV MT oncogene.CrossRefPubMed
23.
Zurück zum Zitat Daly R: The Grb7 family of signalling proteins. Cell Signal. 1998, 10: 613-618. 10.1016/S0898-6568(98)00022-9.CrossRefPubMed Daly R: The Grb7 family of signalling proteins. Cell Signal. 1998, 10: 613-618. 10.1016/S0898-6568(98)00022-9.CrossRefPubMed
24.
Zurück zum Zitat He W, Rose D, Olefsky J, Gustafson T: Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J Biol Chem. 1998, 273: 6860-6867. 10.1074/jbc.273.12.6860. See [25•].CrossRefPubMed He W, Rose D, Olefsky J, Gustafson T: Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J Biol Chem. 1998, 273: 6860-6867. 10.1074/jbc.273.12.6860. See [25•].CrossRefPubMed
25.
Zurück zum Zitat Kasus-Jacobi A, Perdereau D, Auzan C, et al: Identification of the rat adapter Grb14 as an inhibitor of insulin actions. J Biol Chem. 1998, 273: 26026-26035. 10.1074/jbc.273.40.26026. These two papers demonstrate the presence of a novel protein–protein interaction region (the BPS domain) in Grb10 and Grb14, which targets the activated kinase domain of the insulin receptor and IGF-I receptor. This may contribute to modulation of insulin receptor/IGF-I receptor signalling by these adaptors.CrossRefPubMed Kasus-Jacobi A, Perdereau D, Auzan C, et al: Identification of the rat adapter Grb14 as an inhibitor of insulin actions. J Biol Chem. 1998, 273: 26026-26035. 10.1074/jbc.273.40.26026. These two papers demonstrate the presence of a novel protein–protein interaction region (the BPS domain) in Grb10 and Grb14, which targets the activated kinase domain of the insulin receptor and IGF-I receptor. This may contribute to modulation of insulin receptor/IGF-I receptor signalling by these adaptors.CrossRefPubMed
26.
Zurück zum Zitat Stein D, Wu J, Fuqua SAW, et al: The SH2 domain protein Grb-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994, 13: 1331-1340.PubMedPubMedCentral Stein D, Wu J, Fuqua SAW, et al: The SH2 domain protein Grb-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994, 13: 1331-1340.PubMedPubMedCentral
27.
Zurück zum Zitat Fiddes RJ, Campbell DH, Janes PW, et al: Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem. 1998, 273: 7717-7724. 10.1074/jbc.273.13.7717.CrossRefPubMed Fiddes RJ, Campbell DH, Janes PW, et al: Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem. 1998, 273: 7717-7724. 10.1074/jbc.273.13.7717.CrossRefPubMed
28.
Zurück zum Zitat Dong L, Du H, Porter S, et al: Cloning, chromosome localization, expression and characterization of a Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10γ. J Biol Chem. 1997, 272: 29104-29112. 10.1074/jbc.272.46.29104.CrossRefPubMed Dong L, Du H, Porter S, et al: Cloning, chromosome localization, expression and characterization of a Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10γ. J Biol Chem. 1997, 272: 29104-29112. 10.1074/jbc.272.46.29104.CrossRefPubMed
29.
Zurück zum Zitat Daly RJ, Sanderson GM, Janes PJ, Sutherland RL: Cloning and characterization of Grb14, a novel member of the Grb7 gene family. J Biol Chem. 1996, 271: 12502-12510. 10.1074/jbc.271.21.12502.CrossRefPubMed Daly RJ, Sanderson GM, Janes PJ, Sutherland RL: Cloning and characterization of Grb14, a novel member of the Grb7 gene family. J Biol Chem. 1996, 271: 12502-12510. 10.1074/jbc.271.21.12502.CrossRefPubMed
30.
Zurück zum Zitat Tanaka S, Mori M, Akiyoshi T, et al: A novel variant of human Grb7 is associated with invasive esophageal carcinoma. J Clin Invest. 1998, 102: 821-827. This paper describes an association between the expression of a novel Grb7 variant and the invasive and metastatic potential of oesophageal cancers, and also demonstrates that downregulation of Grb7 expression by an antisense strategy inhibits invasion of oesophageal cancer cells in vitro.CrossRefPubMedPubMedCentral Tanaka S, Mori M, Akiyoshi T, et al: A novel variant of human Grb7 is associated with invasive esophageal carcinoma. J Clin Invest. 1998, 102: 821-827. This paper describes an association between the expression of a novel Grb7 variant and the invasive and metastatic potential of oesophageal cancers, and also demonstrates that downregulation of Grb7 expression by an antisense strategy inhibits invasion of oesophageal cancer cells in vitro.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Miyoshi N, Kuroiwa Y, Kohda T, et al: Identification of the Meg1/Grb10 imprinted gene on mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome gene. Proc Natl Acad Sci USA. 1998, 95: 1102-1107. 10.1073/pnas.95.3.1102.CrossRefPubMedPubMedCentral Miyoshi N, Kuroiwa Y, Kohda T, et al: Identification of the Meg1/Grb10 imprinted gene on mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome gene. Proc Natl Acad Sci USA. 1998, 95: 1102-1107. 10.1073/pnas.95.3.1102.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000, Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000,
33.
Zurück zum Zitat Schuuring E, Vernoeven E, Litvinov S, Michalides RJAM: The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell substratum contact sites. Mol Cell Biol. 1993, 13: 2891-2898.CrossRefPubMedPubMedCentral Schuuring E, Vernoeven E, Litvinov S, Michalides RJAM: The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell substratum contact sites. Mol Cell Biol. 1993, 13: 2891-2898.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Huang C, Ni Y, Wang T, et al: Down-regulation of the filamentous actin cross-linking activity of cortactin by Src-mediated tyrosine phosphorylation. J Biol Chem. 1997, 272: 13911-13915. 10.1074/jbc.272.21.13911.CrossRefPubMed Huang C, Ni Y, Wang T, et al: Down-regulation of the filamentous actin cross-linking activity of cortactin by Src-mediated tyrosine phosphorylation. J Biol Chem. 1997, 272: 13911-13915. 10.1074/jbc.272.21.13911.CrossRefPubMed
35.
Zurück zum Zitat Huang C, Liu J, Haudenschild C, Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem. 1998, 273: 25770-25776. 10.1074/jbc.273.40.25770. This is the first demonstration that tyrosine phosphorylation of EMS1/cortactin on sites phosphorylated by c-Src in vitro and in vivo is required for the increase in cell motility induced by EMS1/cortactin overexpression.CrossRefPubMed Huang C, Liu J, Haudenschild C, Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem. 1998, 273: 25770-25776. 10.1074/jbc.273.40.25770. This is the first demonstration that tyrosine phosphorylation of EMS1/cortactin on sites phosphorylated by c-Src in vitro and in vivo is required for the increase in cell motility induced by EMS1/cortactin overexpression.CrossRefPubMed
36.
Zurück zum Zitat Patel A, Schechter G, Wasilenko W, Somers K: Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene. 1998, 16: 3227-3232. 10.1038/sj/onc/1201850.CrossRefPubMed Patel A, Schechter G, Wasilenko W, Somers K: Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene. 1998, 16: 3227-3232. 10.1038/sj/onc/1201850.CrossRefPubMed
37.
Zurück zum Zitat Fantl V, Smith R, Brookes S, Dickson C, Peters G: Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv. 1993, 18: 77-94.PubMed Fantl V, Smith R, Brookes S, Dickson C, Peters G: Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv. 1993, 18: 77-94.PubMed
38.
Zurück zum Zitat Hui R, Campbell D, Lee C, et al: EMS1 amplification can occur independently of CCND1 or INT2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene. 1997, 15: 1617-1623. 10.1038/sj/onc/1201311. The finding that EMS1 amplification, unlike that of CCND1, is associated with poor prognosis in ER-negative patients suggests that EMS1 function is regulated differently in this patient subset, possibly due to overexpression of the EGF receptor and erbB2.CrossRefPubMed Hui R, Campbell D, Lee C, et al: EMS1 amplification can occur independently of CCND1 or INT2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene. 1997, 15: 1617-1623. 10.1038/sj/onc/1201311. The finding that EMS1 amplification, unlike that of CCND1, is associated with poor prognosis in ER-negative patients suggests that EMS1 function is regulated differently in this patient subset, possibly due to overexpression of the EGF receptor and erbB2.CrossRefPubMed
39.
Zurück zum Zitat Hui R, Ball J, Macmillan R, et al: EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene. 1998, 17: 1053-1059. 10.1038/sj/onc/1202023.CrossRefPubMed Hui R, Ball J, Macmillan R, et al: EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene. 1998, 17: 1053-1059. 10.1038/sj/onc/1202023.CrossRefPubMed
40.
Zurück zum Zitat van Damme H, Brok H, Schuuring-Scholtes E, Schuuring E: The redistribution of cortactin into cell-matrix contact sites in human carcinoma cells with 11q13 amplification is associated with both overexpression and post-translational modification. J Biol Chem. 1997, 272: 7374-7380. 10.1074/jbc.272.11.7374.CrossRefPubMed van Damme H, Brok H, Schuuring-Scholtes E, Schuuring E: The redistribution of cortactin into cell-matrix contact sites in human carcinoma cells with 11q13 amplification is associated with both overexpression and post-translational modification. J Biol Chem. 1997, 272: 7374-7380. 10.1074/jbc.272.11.7374.CrossRefPubMed
41.
Zurück zum Zitat Campbell D, Sutherland R, Daly R: Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res. 1999, 59: 5376-5385. This study identified phosphorylation by the MAPKs as a mechanism for regulation of EMS1 function by the EGF receptor.PubMed Campbell D, Sutherland R, Daly R: Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res. 1999, 59: 5376-5385. This study identified phosphorylation by the MAPKs as a mechanism for regulation of EMS1 function by the EGF receptor.PubMed
Metadaten
Titel
Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates
verfasst von
Rania Kairouz
Roger J Daly
Publikationsdatum
01.06.2000
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 3/2000
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr54

Weitere Artikel der Ausgabe 3/2000

Breast Cancer Research 3/2000 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.